You are here

Article Text

Article menu

Download PDFPDF

Plenary sessions
Plenary 1
IGCS19-0575
3 Translating endometrial molecular risk stratification to endometrioid ovarian carcinoma: a novel application of precision medicine
Free
  1. P Krämer1,
  2. A Talhouk2,
  3. T Bosse3,
  4. F Heitz4,
  5. N Singh5,
  6. F Kommoss6,
  7. B Krämer1,
  8. A Hartkopf1,
  9. S Brucker1,
  10. J McAlpine2,
  11. M Koebel7,
  12. M Anglesio2 and
  13. S Kommoss1
  1. 1Tuebingen University Hospital, Department of Women’s Health, Tuebingen, Germany
  2. 2University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, Canada
  3. 3Leiden University Medical Centre, Department of Pathology, Leiden, The Netherlands
  4. 4Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany
  5. 5Barts Health National Health Service Trust, Department of Pathology, London, UK
  6. 6Heidelberg University Hospital, Institute of Pathology, Heidelberg, Germany
  7. 7University of Calgary and Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, Calgary, Canada

Abstract

Objectives Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared to other ovarian carcinoma histotypes. Nonetheless, patients are still treated according to a “one size fits all” approach. While tumor staging offers some stratification, the development of personalized treatment concepts remain elusive. Our group has recently validated the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), to distinguish clinically relevant prognostic groups. ENOC shares risk factors, genomics, and histology with it’s endometrial counterpart. The aim of our study was to apply and investigate ProMisE in ovarian endometrioid carcinoma.

Methods ProMisE was applied to n=509 ENOC after biomarker-assisted review of endometrioid histotype. Cases were aligned into four groups: low risk POLE mutant (POLE); moderate risk mismatch repair deficient (MMRd); high-risk p53 abnormal (p53abn); and a final moderate risk category lacking these biomarkers (p53wt). Kaplan-Meier and multivariable survival analyses were performed.

Results 4% of cases were POLE, 16% MMRd, 10% p53abn and 71% p53wt. Groups showed distinct progression-free and overall survival (p<0.001), near-identical to profiles of endometrial carcinoma. 5-year PFS was 54% in p53abn, 81% in MMRd, 84% in p53wt, and 100% in POLE cases. ProMisE classes of ENOC were independent of stage and residual disease in multivariable analysis.

Conclusions ProMisE risk classification provides additional prognostic information in a large cohort of ENOC. Our findings support the introduction of ProMisE-stratified treatment algorithms to ultimately improve endometrioid ovarian carcinoma patient care. Further, ENOC may benefit from parallel efforts under investigation in endometrial carcinoma.

https://doi.org/10.1136/ijgc-2019-IGCS.3

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.